A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

What this study is about

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.

Who can join (things the study team will check)

✅ You may be able to join if…

• Participant must be ≥ 18 years of age.
• Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.
• Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
• Parts 2A, 1D, 2D: ccRCC. i) Part 1B: solid tumors with KRAS G12C mutation. ii) Part 2B: NSCLC with KRAS G12C mutation. iii) Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation.
• Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1.
• Participants must have measurable disease per RECIST v1.1.

🚫 You may not be able to join if…

• Untreated central nervous system (CNS) metastases.
• Leptomeningeal metastasis (carcinomatous meningitis).
• Impaired cardiac function or clinically significant cardiac disease.
• For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):. i) History of pneumonitis or interstitial lung disease (ILD). ii) History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
• Other protocol-defined inclusion/exclusion criteria apply.

Where this trial is running

• John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
• Local Institution - 0020, Allentown, Pennsylvania, United States
• The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee, United States
• Local Institution - 0025, Dallas, Texas, United States
• Local Institution - 0031, Brisbane, Queensland, Australia
• Local Institution - 0032, Vancouver, British Columbia, Canada
• Local Institution - 0015, Montreal, Quebec, Canada
• Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus, Québec, Quebec, Canada

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06764771.